Welcome to our dedicated page for Medicine Man news (Ticker: SHWZ), a resource for investors and traders seeking the latest updates and insights on Medicine Man stock.
Medicine Man Technologies, Inc., operating as Schwazze (SHWZ), regularly issues news and updates about its activities as a vertically integrated regional cannabis company with assets in Colorado and New Mexico. This news page aggregates company press releases and third-party coverage related to Schwazze’s operations, financial performance, capital structure, and regulatory developments.
Readers can expect updates on Schwazze’s retail and wholesale operations in Colorado and New Mexico, including announcements of new dispensary openings under banners such as R. Greenleaf and Everest Apothecary, changes to its retail footprint, and commentary on customer experience, pricing, promotions, and product assortment. The company also reports on wholesale penetration and catalog developments in both states.
Schwazze’s news flow frequently includes financial results for specific quarters, with management commentary on revenue trends, gross profit, operating expenses, and adjusted EBITDA, as well as discussions of market conditions in Colorado and New Mexico. The company also provides notices of upcoming conference calls to discuss its results, along with details on how investors and other interested parties can listen to these calls.
Another important category of news involves capital structure and restructuring. Schwazze has issued releases on restructuring certain debt obligations, extending maturities, and adjusting payment terms. It has also announced a Restructuring Support Agreement with an affiliate of Vireo Growth Inc. and other parties, which contemplates an asset sale of a majority of its assets to a new entity and the liquidation and winding down of remaining operations, subject to regulatory approvals and closing conditions.
In addition, Schwazze publishes updates on its SEC reporting status and audit matters, including the transition from its former auditor to Baker Tilly US, LLP, the need to restate certain prior financial statements, and the impact of an SEC Order involving its former auditor. The company has also reported that its common stock will transition to the OTC Expert Market due to delayed filings and has described steps it is taking to become current in its reporting obligations.
Investors and observers can use this news page to follow Schwazze’s disclosures about its cannabis operations in Colorado and New Mexico, its financial and operational performance, and its ongoing restructuring and reporting processes.
Schwazze (OTC: SHWZ) entered a Restructuring Support Agreement on Oct 14, 2025 to sell a majority of its assets to a newly formed NewCo majority-owned by Vireo, pursue an auction with a collateral-agent credit bid, and wind down remaining operations.
The plan contemplates NewCo assuming specified liabilities and discharging all or a majority of the Company’s 13% senior secured notes due Dec 7, 2026, and up to approximately $62 million in financing to refinance seller notes, cover transaction costs, and provide working capital. Closing is subject to regulatory approvals and other conditions.
Schwazze (OTC: SHWZ) announced that its financial statements for fiscal years ended December 31, 2023, and quarterly reports for March 31, June 30, and September 30, 2023, will require restatement due to identified accounting adjustments in technical areas. The Audit Committee made this determination on November 29, 2024, following discussions with Baker Tilly and company management.
The company stated that previously issued reports, press releases, earnings releases, investor presentations, and other financial communications related to these periods should no longer be relied upon. However, Schwazze does not expect these corrections to negatively impact its revenue, adjusted EBITDA, cash from operations, or cash position materially.
Schwazze announced preliminary Q3 2024 financial results, showing significant improvements in profitability and positive cash flow from operations. The company expects revenue of approximately $42 million, adjusted EBITDA of around $11 million, and cash flow from operations at $0.2 million. At quarter-end, Schwazze held $11 million in cash and equivalents, with a debt of $196 million.
The company attributes these gains to enhanced pricing strategies, improved in-store experiences, and better product quality, leading to increased store traffic in Colorado and New Mexico. However, due to a re-review process with new auditor Baker Tilly, there will be a delay in filing the Form 10-Q for Q3 2024. This delay is necessitated by the need to re-audit prior financial statements impacted by the SEC's order against previous auditor BF Borgers.
Schwazze (OTC: SHWZ) reported Q2 2024 financial results, showing quarter-over-quarter growth across key metrics. Total revenue increased 2% year-over-year to $43.2 million. Gross profit was $19.0 million (44.0% of revenue), down from 54.4% in Q2 2023. The company reported a net loss of $13.9 million and Adjusted EBITDA of $9.0 million.
Schwazze implemented growth and optimization initiatives, including enhancing customer experience and expanding market share in Colorado and New Mexico. The company closed underperforming stores, streamlined operations, and extended debt maturities. Wholesale penetration increased to approximately 34% in Colorado and 35% in New Mexico.
Schwazze (OTC: SHWZ) (Cboe CA: SHWZ) has scheduled its Second Quarter 2024 Conference Call for August 13, 2024, at 5:00 p.m. ET. The company will discuss financial and operational results for the quarter ended June 30, 2024. A press release detailing the results will be issued prior to the call.
The conference call will be accessible via toll-free and international dial-in numbers, as well as a live webcast on the company's investor relations website. A replay will be available after the call. Interested parties can submit questions in advance by emailing ir@schwazze.com.
Schwazze, operating as Medicine Man Technologies (OTCPK: SHWZ), has restructured its $15 million Altmore Loan and $17 million R. Greenleaf Promissory Note, both previously due in February 2025. The new agreement extends the maturities to November 2025, reduces the Altmore Loan's quarterly principal payments from $750,000 to $300,000, and introduces a new quarterly administrative fee of $75,000. The interest rates remain unchanged at 15% for the Altmore Loan and 5% for the R. Greenleaf Promissory Note. This restructuring provides Schwazze with financial flexibility to pursue growth initiatives in Colorado and New Mexico.
Medicine Man Technologies, operating as Schwazze (OTCQX: SHWZ, Cboe CA: SHWZ), announced a transition to the OTC Expert Market due to delays in filing its Form 10-Q for Q1 2024. The delay stems from an SEC Order against the company's previous auditor, BF Borgers, dismissed in April 2024, for failing PCAOB standards. New auditor Baker Tilly needs additional time to review prior periods and re-audit fiscal 2023 and 2022 financials. Schwazze is also seeking an MCTO from the Ontario Securities Commission, which would allow public trading of shares while restricting executive trades. The company is working to promptly meet SEC reporting obligations.
Medicine Man Technologies, operating as Schwazze (OTCQX: SHWZ), has announced the grand opening of its 35th dispensary in New Mexico. The new store is located at 242 US-550, Bernalillo, NM, and will operate from 8:00 a.m. to 11:00 p.m. Monday through Saturday and 8:00 a.m. to 9:00 p.m. on Sundays. Schwazze's Senior VP of New Mexico Retail, Ken Bair, expressed excitement about expanding the company's presence. The grand opening includes a ribbon-cutting ceremony by the New Mexico Cannabis Chamber of Commerce and events with local vendors. The Bernalillo location is part of Schwazze's strategy to grow its retail footprint, now totaling 35 dispensaries in the state under the R. Greenleaf and Everest brands.
Schwazze, operating as Medicine Man Technologies, announced its Q1 2024 financial results, showcasing a 4% revenue increase to $41.6 million compared to Q1 2023. However, gross profit dropped to $17.9 million from $21.8 million due to pricing pressure and lower volumes. Operating expenses rose to $20.6 million, leading to a net loss of $16.1 million versus a net income of $1.7 million last year. Adjusted EBITDA fell to $7.3 million from $14.5 million. Despite challenges, Schwazze expanded its footprint with new store openings and increased wholesale penetration. Cash reserves stood at $13.2 million with a total debt of $159.7 million.
Medicine Man Technologies, Inc., operating as Schwazze, will hold a conference call on May 15, 2024, to discuss its first-quarter financial and operational results. The call will be followed by a Q&A session, and interested parties can submit questions in advance.